Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:1168-1172

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wever, R.
Right arrow Articles by Rabelink, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wever, R.
Right arrow Articles by Rabelink, T.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*(L)-ARGININE
*CHOLESTEROL
*NITRIC OXIDE
Related Collections
Right arrow Cardio-renal physiology/pathophysiology
Right arrow Pathophysiology
Right arrow Risk Factors
Right arrow Endothelium/vascular type/nitric oxide
(Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:1168-1172.)
© 1999 American Heart Association, Inc.


Vascular Biology

Nitric Oxide Production Is Reduced in Patients With Chronic Renal Failure

Robert Wever; Peter Boer; Michel Hijmering; Erik Stroes; Marianne Verhaar; John Kastelein; Kees Versluis; Fija Lagerwerf; Herman van Rijn; Hein Koomans; Ton Rabelink

From the Department of Clinical Chemistry (R.W., H.v.R.), and the Department of Nephrology and Hypertension (P.B., M.H., E.S., M.V., H.K., T.R.), University Hospital Utrecht, The Netherlands; the U-Gene Clinical Pharmacology Unit, Utrecht, The Netherlands (M.H.); the Department of Vascular Medicine, University Medical Center, Amsterdam, The Netherlands (J.K.); and the Bijvoet Center for Biomolecular Research, Department of Mass Spectrometry, Utrecht University, The Netherlands (K.V., F.L.).

Correspondence to Peter Boer, University Hospital Utrecht, Deptartment of Nephrology and Hypertension, Room F03.226, PO Box 85500, 3508 GA Utrecht, The Netherlands. E-mail p.boer{at}digd.azu.nl

Abstract—In patients with chronic renal failure (CRF), atherosclerosis is a major cause of cardiovascular morbidity and mortality. Generally, atherosclerosis has been associated with a reduced bioavailability of nitric oxide (NO). Experimental studies have indicated the presence of enhanced NO degradation by reactive oxygen species as well as decreased NO production as possible causes for this reduced NO bioavailability. So far, the question whether or not NO production is impaired in patients with CRF has never been investigated. Therefore, we measured whole body NO production in 7 patients with CRF, and in 7 matched healthy subjects. To assess the relative importance of a dysfunction of NO synthase (NOS), we compared the NO production of these patients to that of 2 other groups known to have endothelial dysfunction, ie, 7 patients with familial hypercholesterolemia (FH) who did not yet have signs of clinical cardiovascular disease (all nonsmokers), and 5 cigarette smokers. These groups were also compared with 7 nonsmoking, age-matched healthy subjects. Whole body NO production, determined as in vivo arginine-to-citrulline conversion, was assessed by giving an intravenous infusion of [15N2]-arginine as a substrate for NOS and measuring isotopic plasma enrichment of [15N]-citrulline by LC-MS. NO production in the CRF patients (0.13±0.02 µmol · kg–1 · h–1) was significantly lower (P<0.05) than in the corresponding control group (0.23±0.09 µmol · kg–1 · h–1). NO production also tended to be lower in the FH patients (0.16±0.04 µmol · kg–1 · h–1), but the difference with the corresponding control group did not reach significance (0.22±0.06 µmol · kg–1 · h–1). In the group of smokers, NO production was similar to that in nonsmokers (0.22±0.09 µmol · kg–1 · h–1). In conclusion, it is demonstrated for the first time that basal whole body NO production is reduced in patients with CRF. This finding implies that therapeutic interventions to endothelial dysfunction in these patients should be primarily directed toward improvement of NO production. The finding of only a tendency toward reduction of NO production in patients with FH and the absence of a reduction in cigarette smokers suggests that other mechanisms such as enhanced NO degradation may be involved in the decrease of NO bioavailability in these groups.


Key Words: nitric oxide • chronic renal failure • atherosclerosis • endothelium • hypercholesterolemia




This article has been cited by other articles:


Home page
J. Am. Soc. Nephrol.Home page
G. S. D. Marco, S. Reuter, U. Hillebrand, S. Amler, M. Konig, E. Larger, H. Oberleithner, E. Brand, H. Pavenstadt, and M. Brand
The Soluble VEGF Receptor sFlt1 Contributes to Endothelial Dysfunction in CKD
J. Am. Soc. Nephrol., October 1, 2009; 20(10): 2235 - 2245.
[Abstract] [Full Text] [PDF]


Home page
Ther Adv Respir DisHome page
M. Yigla, R. Banderski, Z. S. Azzam, S. A. Reisner, and F. Nakhoul
Arterio-venous access in end-stage renal disease patients and pulmonary hypertension
Therapeutic Advances in Respiratory Disease, April 1, 2008; 2(2): 49 - 53.
[Abstract] [PDF]


Home page
Clin. Chem.Home page
R. Maas, E. Schwedhelm, L. Kahl, H. Li, R. Benndorf, N. Luneburg, U. Forstermann, and R. H. Boger
Simultaneous Assessment of Endothelial Function, Nitric Oxide Synthase Activity, Nitric Oxide-Mediated Signaling, and Oxidative Stress in Individuals with and without Hypercholesterolemia
Clin. Chem., February 1, 2008; 54(2): 292 - 300.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
C. Baylis
Nitric oxide deficiency in chronic kidney disease
Am J Physiol Renal Physiol, January 1, 2008; 294(1): F1 - F9.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
E. L. Schiffrin, M. L. Lipman, and J. F.E. Mann
Chronic Kidney Disease: Effects on the Cardiovascular System
Circulation, July 3, 2007; 116(1): 85 - 97.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. M. Boulanger, N. Amabile, A. P. Guerin, B. Pannier, A. S. Leroyer, Z. Mallat, C. Nguyen, A. Tedgui, and G. M. London
In Vivo Shear Stress Determines Circulating Levels of Endothelial Microparticles in End-Stage Renal Disease
Hypertension, April 1, 2007; 49(4): 902 - 908.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
F. H. Verbeke, M. Agharazii, P. Boutouyrie, B. Pannier, A. P. Guerin, and G. M. London
Local Shear Stress and Brachial Artery Functions in End-Stage Renal Disease
J. Am. Soc. Nephrol., February 1, 2007; 18(2): 621 - 628.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
G. M. London, A. P. Guerin, F. H. Verbeke, B. Pannier, P. Boutouyrie, S. J. Marchais, and F. Metivier
Mineral Metabolism and Arterial Functions in End-Stage Renal Disease: Potential Role of 25-Hydroxyvitamin D Deficiency
J. Am. Soc. Nephrol., February 1, 2007; 18(2): 613 - 620.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
A. Erdely, G. Freshour, Y.-L. Tain, K. Engels, and C. Baylis
DOCA/NaCl-induced chronic kidney disease: a comparison of renal nitric oxide production in resistant and susceptible rat strains
Am J Physiol Renal Physiol, January 1, 2007; 292(1): F192 - F196.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
F. Stam, C. van Guldener, A. Becker, J. M. Dekker, R. J. Heine, L. M. Bouter, and C. D.A. Stehouwer
Endothelial Dysfunction Contributes to Renal Function-Associated Cardiovascular Mortality in a Population with Mild Renal Insufficiency: The Hoorn Study
J. Am. Soc. Nephrol., February 1, 2006; 17(2): 537 - 545.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
A. Erdely, G. Freshour, and C. Baylis
Resistance to renal damage by chronic nitric oxide synthase inhibition in the Wistar-Furth rat
Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2006; 290(1): R66 - R72.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
N. Amabile, A. P. Guerin, A. Leroyer, Z. Mallat, C. Nguyen, J. Boddaert, G. M. London, A. Tedgui, and C. M. Boulanger
Circulating Endothelial Microparticles Are Associated with Vascular Dysfunction in Patients with End-Stage Renal Failure
J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3381 - 3388.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
X. J, L. G, W. P, V. H, Y. X, L. Y, W. Y, P. A, C. S, D. GV, et al.
Kidney and Blood Pressure--The Story Unfolds: Renalase Is a Novel, Soluble Monoamine Oxidase That Regulates Cardiac Function and Blood Pressure. J Clin Invest
J. Am. Soc. Nephrol., September 1, 2005; 16(9): 2521 - 2527.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
F. Nakhoul, M. Yigla, R. Gilman, S. A. Reisner, and Z. Abassi
The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access
Nephrol. Dial. Transplant., August 1, 2005; 20(8): 1686 - 1692.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
T. Kihara, Y. Miyata, M. Furukawa, M. Noguchi, M. Nishikido, S. Koga, and H. Kanetake
Predictive value of serum macrophage colony-stimulating factor for development of aortic calcification in haemodialysis patients: a 6 year longitudinal study
Nephrol. Dial. Transplant., August 1, 2005; 20(8): 1647 - 1652.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
F. Mittermayer, G. Schaller, J. Pleiner, A. Vychytil, G. Sunder-Plassmann, W. H. Horl, and M. Wolzt
Asymmetrical Dimethylarginine Plasma Concentrations Are Related to Basal Nitric Oxide Release but Not Endothelium-Dependent Vasodilation of Resistance Arteries in Peritoneal Dialysis Patients
J. Am. Soc. Nephrol., June 1, 2005; 16(6): 1832 - 1838.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
J. Passauer, F. Pistrosch, E. Bussemaker, G. Lassig, K. Herbrig, and P. Gross
Reduced Agonist-Induced Endothelium-Dependent Vasodilation in Uremia Is Attributable to an Impairment of Vascular Nitric Oxide
J. Am. Soc. Nephrol., April 1, 2005; 16(4): 959 - 965.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
J. Trujillo, V. Ramirez, J. Perez, I. Torre-Villalvazo, N. Torres, A. R. Tovar, R. M. Munoz, N. Uribe, G. Gamba, and N. A. Bobadilla
Renal protection by a soy diet in obese Zucker rats is associated with restoration of nitric oxide generation
Am J Physiol Renal Physiol, January 1, 2005; 288(1): F108 - F116.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. M. Hallemeesch, B. J. A. Janssen, W. J. de Jonge, P. B. Soeters, W. H. Lamers, and N. E. P. Deutz
NO production by cNOS and iNOS reflects blood pressure changes in LPS-challenged mice
Am J Physiol Endocrinol Metab, October 1, 2003; 285(4): E871 - E875.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
F. Locatelli, B. Canaud, K.-U. Eckardt, P. Stenvinkel, C. Wanner, and C. Zoccali
Oxidative stress in end-stage renal disease: an emerging threat to patient outcome
Nephrol. Dial. Transplant., July 1, 2003; 18(7): 1272 - 1280.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
P. Fiorina, F. Folli, F. Bertuzzi, P. Maffi, G. Finzi, M. Venturini, C. Socci, A. Davalli, E. Orsenigo, L. Monti, et al.
Long-Term Beneficial Effect of Islet Transplantation on Diabetic Macro-/Microangiopathy in Type 1 Diabetic Kidney-Transplanted Patients
Diabetes Care, April 1, 2003; 26(4): 1129 - 1136.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
A. Avogaro, G. Toffolo, E. Kiwanuka, S. V. de Kreutzenberg, P. Tessari, and C. Cobelli
L-Arginine-Nitric Oxide Kinetics in Normal and Type 2 Diabetic Subjects: A Stable-Labelled 15N Arginine Approach
Diabetes, March 1, 2003; 52(3): 795 - 802.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
Z. A. Massy, D. Borderie, T. Nguyen-Khoa, T. B. Drueke, O. G. Ekindjian, and B. Lacour
Increased plasma S-nitrosothiol levels in chronic haemodialysis patients
Nephrol. Dial. Transplant., January 1, 2003; 18(1): 153 - 157.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
J.-M. Corpataux, E. Haesler, P. Silacci, H. B. Ris, and D. Hayoz
Low-pressure environment and remodelling of the forearm vein in Brescia-Cimino haemodialysis access
Nephrol. Dial. Transplant., June 1, 2002; 17(6): 1057 - 1062.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
S. COMBET, M.-L. FERRIER, M. V. LANDSCHOOT, M. STOENOIU, P. MOULIN, T. MIYATA, N. LAMEIRE, and O. DEVUYST
Chronic Uremia Induces Permeability Changes, Increased Nitric Oxide Synthase Expression, and Structural Modifications in the Peritoneum
J. Am. Soc. Nephrol., October 1, 2001; 12(10): 2146 - 2157.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
J. T. Kielstein, J. C. Frolich, H. Haller, and D. Fliser
ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease?
Nephrol. Dial. Transplant., September 1, 2001; 16(9): 1742 - 1745.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
J. Borawski, B. Naumnik, K. Pawlak, and M. Mysliwiec
Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with pre-dialysis blood pressure and the acute phase response
Nephrol. Dial. Transplant., July 1, 2001; 16(7): 1442 - 1447.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
G. D. Thomas, W. Zhang, and R. G. Victor
Nitric Oxide Deficiency as a Cause of Clinical Hypertension: Promising New Drug Targets for Refractory Hypertension
JAMA, April 25, 2001; 285(16): 2055 - 2057.
[Full Text] [PDF]


Home page
DiabetesHome page
P. Fiorina, E. La Rocca, M. Venturini, F. Minicucci, I. Fermo, R. Paroni, A. D’Angelo, M. Sblendido, V. Di Carlo, M. Cristallo, et al.
Effects of Kidney-Pancreas Transplantation on Atherosclerotic Risk Factors and Endothelial Function in Patients With Uremia and Type 1 Diabetes
Diabetes, March 1, 2001; 50(3): 496 - 501.
[Abstract] [Full Text]


Home page
Cardiovasc ResHome page
A.C. Mendes Ribeiro, T.M.C. Brunini, J.C. Ellory, and G.E. Mann
Abnormalities in L-arginine transport and nitric oxide biosynthesis in chronic renal and heart failure
Cardiovasc Res, March 1, 2001; 49(4): 697 - 712.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
J. PASSAUER, E. BÜSSEMAKER, U. RANGE, M. PLUG, and P. GROSS
Evidence In Vivo Showing Increase of Baseline Nitric Oxide Generation and Impairment of Endothelium-Dependent Vasodilation in Normotensive Patients on Chronic Hemodialysis
J. Am. Soc. Nephrol., September 1, 2000; 11(9): 1726 - 1734.
[Abstract] [Full Text]


Home page
Nephrol Dial TransplantHome page
P. Stenvinkel, O. Heimburger, B. Lindholm, G. A. Kaysen, and J. Bergstrom
Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome)
Nephrol. Dial. Transplant., July 1, 2000; 15(7): 953 - 960.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
L.-T. DIJKHORST-OEI, P. BOER, T. J. RABELINK, and H. A. KOOMANS
Nitric Oxide Synthesis Inhibition Does Not Impair Water Immersion-Induced Renal Vasodilation in Humans
J. Am. Soc. Nephrol., July 1, 2000; 11(7): 1293 - 1302.
[Abstract] [Full Text]


Home page
Circ. Res.Home page
E. S. G. Stroes, E. E. van Faassen, M. Yo, P. Martasek, P. Boer, R. Govers, and T. J. Rabelink
Folic Acid Reverts Dysfunction of Endothelial Nitric Oxide Synthase
Circ. Res., June 9, 2000; 86(11): 1129 - 1134.
[Abstract] [Full Text] [PDF]